Spark Therapeutics announced that it has appointed Rogerio Vivaldi, as it's first chief commercial officer. Most recently, Dr. Vivaldi led Minerva Neurosciences in the development of a portfolio of innovative product candidates addressing neuropsychiatric diseases and the successful completion of an initial public offering earlier 2014. At Spark, Dr. Vivaldi will oversee the planned launch of the company's lead product candidate, SPK-RPE65, with
responsibility for global commercial, patient advocacy, market access, and medical affairs operations.